All In Biotech

Drug Trial Radar · NCT02477449

Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers

A Phase I Dose Escalating Study Evaluating the Pharmacokinetics, Tolerability and Safety of Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Mar 2015

Primary completion

Oct 2015

Study completion Oct 2015

Sponsor

Lead sponsor
Lee's Pharmaceutical LimitedIndustry
Sponsor type
Industry
Collaborators
CVie Therapeutics Co. Ltd.
First posted
Jun 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase 1 study to investigate safety of istaroxime in healthy chinese volunteers.

Conditions

  • Healthy

Interventions

  • istaroximeDrug

    8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).

  • 9% Saline (NS)Drug

    infusion for 24 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. safety of istaroxime in healthy volunteers is measured by varition of heart functon, blood pressure and heart ratioTime frame: one week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The 307th hospital of chinese People's liberation army

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.